Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Pharmaceuticals beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, with revenue rising 18.9% year over year to about $83.2 million (up from $70.0 million a year ago) while EPS of $0.28 topped the $0.24 estimate, +16.7%. Revenue of $83.2 million also topped the $80.4 million consensus, +3.4%, and profitability stayed high with gross margin near 92% and operating margin around 56%, alongside operating income of roughly $46.3 million. Net income increased 73.9% to about $37.4 million versus $21.5 million a year ago, and the quarter generated operating cash flow of approximately $52.2 million. Next-period consensus calls for EPS of $0.19 on revenue of $83.6 million.